|Articles|August 12, 2020
- Pharmaceutical Executive-08-01-2020
- Volume 40
- Issue 8
Pharmaceutical Executive, August 2020 Issue (PDF)
Click here for a link to open the Pharmaceutical Executive August 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Pharm Exec’s 19th Annual Industry Auditalmost 6 years ago
AI and Social Listening: Myths vs. Factsalmost 6 years ago
A Good Time to ‘Revamp’ Sales and Marketingalmost 6 years ago
Tapping Compliance Data to Drive Successalmost 6 years ago
Pricing, Innovation, and a Pound of Fleshalmost 6 years ago
Strategic Realignment for a Better Future 1almost 6 years ago
Tackling a ‘Genius Virus’almost 6 years ago
Leaders Need to Hit Pricing Issue Head-Onalmost 6 years ago
The New Data Dynamic: How COVID-19 has Upended Modelalmost 6 years ago
Making Strides in Pharma Gender ParityAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
The Evolving Relationship Between FDA and Biotech
5